Gilead Sciences (NASDAQ:GILD) price target dropped to $95.00, issued a research note today by RBC Capital
- Updated: October 2, 2016
Yesterday Gilead Sciences (NASDAQ:GILD) traded 1.62% higher at $79.12. The company’s 50-day moving average is $79.40 and its 200-day moving average is $85.53. The last closing price is down -7.50% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 11,031,567 shares of the stock traded hands, up from an average trading volume of 10,503,600
In a report released on 10/03/2016 RBC Capital reduced the stock price target of Gilead Sciences (NASDAQ:GILD) from $105.00 to $95.00 indicating a possible upside of 0.20%.
Previously on 9/27/2016, Leerink Partners reported on Gilead Sciences (NASDAQ:GILD) reduced the target price from $112.00 to $94.00. At the time, this indicated a possible upside of 0.17%.
See Chart Below
Gilead Sciences has a 52 week low of $76.67 and a 52 week high of $111.11 with a P/E ratio of 6.94 GILD’s total market value is presently $0.
A total of 19 brokers have issued a research note on the company. 7 firms rating the stock a strong buy, 9 firms rating the company a buy, nine equity analysts rating the stock a hold, zero analysts rating the company a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $111.05.
Brief Synopsis On Gilead Sciences (NASDAQ:GILD)
Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.